Recombinant human decorin upregulates P57KIP2 expression in HepG2 hepatoma cell lines

Molecular Medicine Reports

Volumn 8, Issue 2, 2013, Pages 511-516

  Hamid, Abdu Selim ^a   Li, Jinran ^b   Wang, Yali ^a   Wu, Xiaodong ^a   Ahmed Ali, Hassan Abdellah ^a   Du, Zhenwu ^a   Bo, Lihua ^a   Zhang, Yucheng ^a   Zhang, Guizhen ^a  

^a CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

Cyclin dependent kinase inhibitors; Hepatocellular carcinoma; HepG2; P57KIP2; Recombinant human decorin

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1C; DECORIN; RECOMBINANT PROTEIN;

APOPTOSIS; ARTICLE; CELL ASSAY; CELL CYCLE; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSIENT TRANSFECTION; UPREGULATION;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P57; DECORIN; GENE EXPRESSION; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; RECOMBINANT PROTEINS;

EID: 84879934068     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1510     Document Type: Article

References (39)

1. Colak D, Chishti MA, Al-Bakheet AB, et al: Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old. Mol Cancer 9: 146, 2010.
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
3. El-Serag HB, Davila JA, Petersen NJ and McGlynn KA: The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139: 817-823, 2003.
4. Zhang MF, Zhang ZY, Fu J, Yang YF and Yun JP: Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. J Transl Med 7: 110, 2009.
5. Jain S, Singhal S, Lee P and Xu R: Molecular genetics of hepatocellular neoplasia. Am J Transl Res 2: 105-118, 2010.
6. McGlynn KA and London WT: Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 19: 3-23, 2005.
7. Sherman M: Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 25: 143-154, 2005.
8. Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-687, 2006.
9. Altekruse SF, McGlynn KA and Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27: 1485-1491, 2009.
10. Nguyen MH, Whittemore AS, Garcia RT, et al: Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol 2: 820-824, 2004.
11. Iozzo RV: Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67: 609-652, 1998.
12. Iozzo RV, Moscatello DK, McQuillan DJ and Eichstetter I: Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 274: 4489-4492, 1999.
13. Reed CC and Iozzo RV: The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj J 19: 249-255, 2002.
14. Baghy K, Dezso K, László V, et al: Ablation of the decorin gene enhances experimental hepatic fibrosis and impairs hepatic healing in mice. Lab Invest 91: 439-451, 2011.
15. Gu Y, Zhang S, Wu Q, et al: Differential expression of decorin, EGFR and cyclin D1 during mammary gland carcinogenesis in TA2 mice with spontaneous breast cancer. J Exp Clin Cancer Res 29: 6, 2010.
16. Moscatello DK, Santra M, Mann DM, McQuillan DJ, Wong AJ and Iozzo RV: Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest 101: 406-412, 1998.
17. Csordás G, Santra M, Reed CC, et al: Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem 275: 32879-32887, 2000.
18. Bi X, Tong C, Dockendorff A, et al: Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis 29: 1435-1440, 2008.
19. Besson A, Dowdy SF and Roberts JM: CDK inhibitors: cell cycle regulators and beyond. Dev Cell 14: 159-169, 2008.
20. Kavanagh E and Joseph B: The hallmarks of CDKN1C (p57, KIP2) in cancer. Biochim Biophys Acta 1816: 50-56, 2011.
21. Pateras IS, Apostolopoulou K, Koutsami M, et al: Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer. Int J Cancer 119: 2546-2556, 2006.
22. Oya M and Schulz WA: Decreased expression of p57(KIP2)mRNA in human bladder cancer. Br J Cancer 83: 626-631, 2000.
23. Li JQ, Wu F, Usuki H, et al: Loss of p57KIP2 is associated with colorectal carcinogenesis. Int J Oncol 23: 1537-1543, 2003.
24. Larson PS, Schlechter BL, King CL, et al: CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer. BMC Cancer 8: 68, 2008.
25. Ito Y, Takeda T, Sakon M, Tsujimoto M, Monden M and Matsuura N: Expression of p57/Kip2 protein in hepatocellular carcinoma. Oncology 61: 221-225, 2001.
26. Atasoy P, Yilmaz E, Bozdogan O, Ayva S and Batislam E: Expression profile and prognostic importance in prostate lesions of the reverse transcriptase component of human telomerase (hTERT) and of cyclin-dependent kinase inhibitor p57 (p57kip2a). Int Urol Nephrol 41: 55-60, 2009.
27. Guo H, Lv Y, Tian T, et al: Downregulation of p57 accelerates the growth and invasion of hepatocellular carcinoma. Carcinogenesis 32: 1897-1904, 2011.
28. Zhang Y, Wang Y, Du Z, et al: Recombinant human decorin suppresses liver HepG2 carcinoma cells by p21 upregulation. Onco Targets Ther 5: 143-152, 2012.
29. Hu Y, Sun H, Owens RT, et al: Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia 11: 1042-1053, 2009.
30. De Luca A, Santra M, Baldi A, Giordano A and Iozzo RV: Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem 271: 18961-18965, 1996.
31. Seidler DG, Goldoni S, Agnew C, et al: Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J Biol Chem 281: 26408-26418, 2006.
32. Lakhani SA, Masud A, Kuida K, et al: Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 311: 847-851, 2006.
33. Ma Y and Cress WD: Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicity. Oncogene 26: 3532-3540, 2007.
34. Scandura JM, Boccuni P, Massagué J and Nimer SD: Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. Proc Natl Acad Sci USA 101: 15231-15236, 2004.
35. Nan KJ, Guo H, Ruan ZP, Jing Z and Liu SX: Expression of p57(kip2) and its relationship with clinicopathology, PCNA and p53 in primary hepatocellular carcinoma. World J Gastroenterol 11: 1237-1240, 2005.
36. Biaoxue R, Xiguang C, Hua L, et al: Decreased expression of decorin and p57(KIP2) correlates with poor survival and lymphatic metastasis in lung cancer patients. Int J Biol Markers 26: 9-21, 2011.
37. Shen L, Toyota M, Kondo Y, et al: Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 101: 4131-4136, 2003.
38. Nakai S, Masaki T, Shiratori Y, et al: Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival. Int J Oncol 20: 769-775, 2002.
39. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K and Tokuda M: Expression of p57kip2 and its clinical relevance in epithelial ovarian tumors. Anticancer Res 22: 3191-3196, 2002.